Trials / Completed
CompletedNCT03680417
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 590 (actual)
- Sponsor
- PT Bio Farma · Industry
- Sex
- All
- Age
- 9 Months – 47 Months
- Healthy volunteers
- Accepted
Summary
to assess safety and immunogenicity of measles-rubella (MR) routine immunization in Indonesian Children and Infants
Detailed description
* to asses serious immediate systemic events, * to assess local and systemic reaction after Measles-Rubella (MR) vaccine in infants and children, * to evaluate protectivity and antibody response to measles and rubella after 1 dose of MR vaccine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Measles-Rubella (MR) Vaccine | Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus. |
Timeline
- Start date
- 2017-11-16
- Primary completion
- 2018-02-26
- Completion
- 2018-08-01
- First posted
- 2018-09-21
- Last updated
- 2019-09-12
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT03680417. Inclusion in this directory is not an endorsement.